This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Analysts' Actions: AIG, DOW, EZPW, FOSL

Stocks in this article: AIG DOW FOSL EZPW UA

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Aetna (AET) was downgraded from Neutral to Sell at Goldman Sachs. Commercial margins could continue to fall, Goldman said. $45 price target.

AIG (AIG - Get Report) was upgraded to Buy at Goldman Sachs. Chart is is showing progress, and the company has multiple potential catalysts, Goldman said. $40 price target.

CF Industries (CF) was downgraded at Dahlman Rose. Higher corn supplies could weigh on prices, Dahlman Rose said. $155 price target.

Dish (DISH) was downgraded to Hold at TheStreet Ratings.

Dow Chemical (DOW - Get Report) was upgraded at Morgan Stanley from Equal-Weight to Overweight. $38 price target. Company should benefit from lower ethane prices, Morgan Stanley said.

EZCorp (EZPW - Get Report) was upgraded at Sterne Agee from Underperform to Neutral. Valuation call, based on a $24 price target, Sterne Agee said.

Fossil (FOSL - Get Report) was upgraded at Benchmark from Hold to Buy. $100 price target. Estimates also cut, given lower expected sales in Europe, Benchmark said.

Fossil was downgraded at JP Morgan from Overweight to Neutral. Company's growth story is in transition, JP Morgan said. $88 price target.

Generac Holdings (GNRC) was downgraded at Goldman Sachs to Neutral from Buy. $30 price target. Risk reward around consensus estimates is now balanced, Goldman said.

Global Partners (GLP) was downgraded to Hold at TheStreet Ratings.

Herbalife (NOK) was downgraded at Caris & Co. from Buy to Average. $39 price target. Expect David Einhorn to weigh on sentiment, Caris said.

Hershey (HSY) was upgraded at Argus from Hold to Buy. $78 price target. Company is realizing higher sales growth, Argus said.

Humana (HUM) was downgraded at Goldman Sachs from Buy to Neutral. Valuation call, based on a $90 price target, Goldman said.

Immunomedics (IMMU) was downgraded to Hold at TheStreet Ratings.

Jive Software (JIVE) was initiated with a Hold rating at Needham. Valuation call, Needham said.

Janus Capital (JNS) was upgraded at Bank of America/Merrill Lynch from Underperform to Neutral. Valuation call, based on an $8.50 price target, Bank of America/Merrill Lynch said.

Magellan Health Services (MGLN) was upgraded at Bank of America/Merrill to Buy from Underperform. $52 price target. Big contract extension derisks outlook, BofA/Merrill said.

Phillips 66 (PSX) was initiated with an Outperform rating at Credit Suisse. $42 price target. Company can deliver above-average growth, Credit Suisse said.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,360.31 -56.54 -0.32%
S&P 500 2,014.11 -7.14 -0.35%
NASDAQ 4,676.8710 -6.5360 -0.14%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs